Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

OnabotulinumtoxinA for Urinary Incontinence from Neurogenic Detrusor Overactivity.

Advertisements

Dorset Healthcare Continence Advisory Service

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 4 Types of urinary diversion

Figure 1 Male infertility and assisted reproduction globally

or multiple system atrophy (MSA)

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 6 Effects of adiponectin on podocyte function

Nat. Rev. Urol. doi: /nrurol

Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo

Figure 5 Types of urinary diversion

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Proportion of patients for whom NEDA

Figure 1 Key elements of the proposed modified Delphi study

Figure 5 Number of AHSCT procedures for

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Common signalling mechanisms, pathways,

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 The development process of the Asian

Figure 1 Differences in bladder cancer between genders

Figure 13 Proposed management of bladder cancer with variant histology

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 3 Algorithm for the determination of the clinical

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Urol. doi: /nrurol

Figure 2 Temporal summation

Figure 6 Image sequence demonstrating coronal cuts on MRI

Nat. Rev. Urol. doi: /nrurol

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Figure 3 Template for standard pelvic lymphadenectomy

Figure 1 Changes in LUT function associated with ageing

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Timing of the effects of deep brain stimulation

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 The grey zone between active

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Fig. 2. Algorithm of treatment for failed endoscopic treatment (ET)

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2016.53 Figure 3 Algorithm for the management of storage symptoms in patients with multiple sclerosis Figure 3 | Algorithm for the management of storage symptoms in patients with multiple sclerosis. Maintaining quality of life, including preservation of renal function is the primary aim of management of these symptoms. At initial presentation, the most conservative approaches should be considered the primary treatments of storage symptoms; although, as patients' disease progresses, more invasive management approaches might be required. BoNT-A, botulinum neurotoxin A; ISC, intermittent self catherization; LUT, lower urinary tract. Phé, V. et al. (2016) Management of neurogenic bladder in patients with multiple sclerosis Nat. Rev. Urol. doi:10.1038/nrurol.2016.53